# Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

> **NCT00274456** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 302 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** ABI-007
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00274456
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-01
- **Primary completion:** 2008-03-01
- **Final completion:** 2011-07-01
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274456, "Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00274456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*